Skip to content


University of Washington spinout Bellwether Bio acquired by Guardant Health

Written by Debra Bouchegnies / April 19, 2019

Jay Shendure, Md, PhD, Professor of Genome Sciences at University of Washington and Rahul Shendure, CEO, Bellwether Bio

Earlier this month, precision oncology company Guardant Health (NASDAQ: GH) announced that it will be acquiring Bellwether Bio, a University of Washington spinout that develops next generation cancer diagnostics using cell-free DNA.

Bellwether Bio emerged from the lab of Genome Sciences Professor Jay Shendure, MD, PhD, who will act as scientific advisor to Guardant Health. Shendure joined the faculty at the Department of Genome Sciences at the UW in 2007 where his research lab focuses on developing and applying new technologies in genomics. Together with the Bellwether Bio team, Guardant Health will further advance its early detection product pipeline.

In 2016, an article about the important work coming out of the Shendure Lab was published in Cell. Co-authored by Bellwether Bio CTO Matthew Snyder, PhD, the article described the foundational underpinnings of a technology with the potential to enable earlier and more accurate noninvasive monitoring of an increasingly broad set of clinical conditions.

“CoMotion at the University of Washington was an invaluable resource throughout our commercialization journey,” says Bellwether Bio CEO Rahul Shendure. “We greatly appreciate their support on patent filing, CoMotion Innovation Gap Fund, STEP funding, and diligent license negotiations.”